Journey Medical (NASDAQ:DERM) Releases Earnings Results

Journey Medical (NASDAQ:DERM) issued its earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03), Yahoo Finance reports. The company had revenue of $14.86 million during the quarter, compared to analysts’ expectations of $13.81 million. Journey Medical had a negative return on equity of 32.83% and a negative net margin of 5.20%. During the same period in the previous year, the company earned ($0.46) EPS.

Journey Medical Price Performance

DERM traded up $0.33 on Tuesday, reaching $4.55. The company’s stock had a trading volume of 17,052 shares, compared to its average volume of 135,557. Journey Medical has a 1 year low of $1.78 and a 1 year high of $8.11. The firm has a 50 day moving average of $5.30. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.94 and a current ratio of 1.21. The firm has a market cap of $91.06 million, a PE ratio of -15.03 and a beta of 0.93.

Analysts Set New Price Targets

DERM has been the subject of a number of analyst reports. Roth Capital upgraded Journey Medical to a “strong-buy” rating in a report on Friday, June 28th. Roth Mkm began coverage on shares of Journey Medical in a report on Friday, June 28th. They set a “buy” rating and a $11.00 price target for the company.

Insiders Place Their Bets

In other news, CFO Joseph Benesch sold 9,324 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $5.47, for a total transaction of $51,002.28. Following the completion of the sale, the chief financial officer now owns 47,331 shares of the company’s stock, valued at $258,900.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 19.42% of the stock is owned by company insiders.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.